JPRN-UMIN000006467已完成1 期
Phase I/II Clinical Study of Fludarabine and Etoposide in Combination with Nelarabine in Pediatric Patients with Refractory or Relapsed Acute T-lymphoblastic leukemia. - JPLSG ALL-RT11
Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)0 个研究点目标入组 31 人开始时间: 2011年10月4日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 31
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 1years-old 至 20years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Have central nervous system involvement. 2. Have history of receiving hematopoietic cell transplantation 3. Secondary T-ALL 4. Have other malignancy 5. Are pregnant or lactating. 6. Have psychiatric disorders that would interfere with consent, study participation, or follow-up. 7. Have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or pancreas.
研究者
相似试验
招募中
Unknown
Investigations into the influence of fludarabine exposure on the outcomeof patients after CAR-T cell therapyC90C83Multiple myeloma and malignant plasma cell neoplasmsNon-follicular lymphomaDRKS00033974niversitätsklinikum Hamburg Eppendorf200
进行中（未招募）
1 期
Phase ll Trial of Fludarabine & Cyclophosphamide followed by Thalidomide for Angioimmunoblastic Lymphoma - AITEUCTR2005-003931-40-GBniversity College London15
进行中（未招募）
不适用
A phase II study in patients with fludarabine refractory CLL: Dasatinib treatment combination for Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL) - D’accord studyEUCTR2008-002236-15-NLAcademic Medical Center
已完成
1 期
Phase I/II study of clofarabine, etoposide and cyclophosphamide (CLEC) chemotherapy in adult patients with refractory or relapse acute lymphoblastic leukemia (JALSG RR-ALL214)acute lymphoblastic leukemia (ALL) which is relapsed or refractory to induction therapy (including the ph chromosome positive ALL)JPRN-UMIN000015373Japan Adult Leukemia Study Group24
已完成
2 期
A phase II trial of high dose cytarabine and fludarabine without anthracycline for patients with core binding factor acute myeloid leukaemia, measuring efficacy, safety and monitoring minimal residual diseaseCore binding factor acute myeloid leukaemiaCancer - Leukaemia - Acute leukaemiaACTRN12605000152628Australasian Leukaemia and Lymphoma Group53